Impact of hepatitis B birth dose on immune response in Pakistani children: an open-label, non-inferiority randomized controlled trial, implications for achieving SDG target

References

• Bloomberg BS, Hepatitis B. The hunt for a killer virus. 1st ed. Princeton (NJ): Princeton University Press; 2003.
   Google Scholar
• World Health Organization. Hepatitis B vaccines: WHO position paper – July 2017. Releve Epidemiol Hebd. 2017;92(27):369–392.
   PubMedGoogle Scholar
• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–1088. doi:10.1016/S0140-6736(16)30579-7.
   PubMed Web of Science ®Google Scholar
• United Nations. Global indicator framework for the sustainable development goals and targets of the 2030 agenda for sustainable development [Internet]. Work of the Statistical Commission pertaining to the 2030 Agenda for Sustainable Development. 2017. p. 1–21. Available from: https://unstats.un.org/sdgs/indicators/Global Indicator Framework_A.RES.71.313 Annex.pdf.
   Google Scholar
• World Health Organization. Global health sector strategy viral hepatitis 2016–2021. Geneva (Switzerland): WHO Press; 2016.
   Google Scholar
• Li X, Dumolard L, Patel M, et al. Implementation of hepatitis B birth dose vaccination – worldwide, 2016. Wkly Epidemiol Rec. 2018;93(7):61–72. Available from: http://www.who.int/wer
   PubMedGoogle Scholar
• Pakistan Medical Research Council. Prevalence of hepatitis B & C in Pakistan. Islamabad (Pakistan): Ministry of Health Government of Pakistan; 2010. p. 121.
   Google Scholar
• Qureshi H, Javaid N, Alam SE, et al. The evidence of mother to child transmission of hepatitis B virus infection in Pakistan and the need for hepatitis B immunization policy change. J Pak Med Assoc. 2014;64(4):403–408.
   PubMed Web of Science ®Google Scholar
• Akbar SMF, Al Mahtab M, Begum F, et al. Implications of birth-dose vaccination against hepatitis B virus in southeast Asia. Vaccines (Basel). 2021;9(4):374. doi:10.3390/vaccines9040374.
   PubMed Web of Science ®Google Scholar
• Puri P. Tackling the hepatitis B disease burdenin India. J Clin Exp Hepatol. 2014;4(4):312–319. doi:10.1016/j.jceh.2014.12.004.
   PubMedGoogle Scholar
• Salehi-Vaziri M, Sadeghi F, Hashiani AA, et al. Hepatitis B virus infection in the general population of Iran: an updated systematic review and meta-analysis. Hepat Mon. 2016;16(4):e35577. doi:10.5812/hepatmon.35577.
   PubMed Web of Science ®Google Scholar
• Paul RC, Rahman M, Wiesen E, et al. Hepatitis B surface antigen seroprevalence among prevaccine and vaccine era children in Bangladesh. Am J Trop Med Hyg. 2018;99(3):764–771. doi:10.4269/ajtmh.17-0721.
   PubMed Web of Science ®Google Scholar
• Wijewantha HS. Liver disease in Sri Lanka. Euroasian J Hepatogastroenterol. 2017;7(1):78–81. doi:10.5005/jp-journals-10018-1217.
   PubMedGoogle Scholar
• Lindqvist H, Duminda Guruge GN, Trollfors B. Age appropriateness of vaccination with recommended childhood vaccines in Sri Lanka. Vaccine X. 2019;2:100016. doi:10.1016/j.jvacx.2019.100016.
   PubMedGoogle Scholar
• Pakistan Health Research Council. Punjab hepatitis action plan. Islamabad (Pakistan); 2019. Available from: https://dgme.punjab.gov.pk/system/files?file=EVL-797%20Evaluation%20Report%20on%20Prevention%20and%20Control%20of%20Hepatitis%20BC%20In%20Punjab%202016-2022.pdf
   Google Scholar
• Pakistan Health Research Council. Sindh Hepatitis Action Plan 2020–2022. Islamabad (Pakistan): PHRC; 2019. Available from: https://phrc.org.pk/assets/sindh-hepatitis-action-plan-final-version.pdf.
   Google Scholar
• Bell S, Blanchard L, Walls H, et al. Value and effectiveness of National Immunization Technical Advisory Groups in low- and middle-income countries: a qualitative study of global and national perspectives. Health Policy Plan. 2019;34(4):271–281. doi:10.1093/heapol/czz027.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme. Geneva (Switzerland): WHO; 2014. Available from: http://apps.who.int/iris/bitstream/handle/10665/111548/9789241506892_eng.pdf;jsessionid=77F05E5EA2D593694B91789BE532CB8A?sequence=1.
   Google Scholar
• Deen JL, Clemens JD. Issues in the design and implementation of vaccine trials in less developed countries. Nat Rev Drug Discov. 2006;5(11):932–940. doi:10.1038/nrd2159.
   PubMed Web of Science ®Google Scholar
• Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective?.  J Infect Dis. 1999;179(2):489–492. doi:10.1086/314578.
   PubMed Web of Science ®Google Scholar
• Poorajlal J, Hooshmad E. Booster dose vaccination for preventing hepatitis B. Cochrane Database Syst Rev. 2016;(6):CD008256.
   Google Scholar
• The Gambia Hepatitis Study Group. The Gambia hepatitis intervention study. Cancer Res. 1987;47(21):5782–5787.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Mitha I; Cutland C, Groome M, et al. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination. Pediatr Infect Dis J. 2011;30(4):68–74.
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Reyes M, Bernal N, et al. A new DTPw-HBV/hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin. 2005;1(5):198–203. doi:10.4161/hv.1.5.2163.
   PubMed Web of Science ®Google Scholar
• Friedman LM, Furberg CD, DeMets DL, et al. Fundamentals of clinical trials. 5th ed. New York (NY): Springer International Publishing; 2015. 550 p.
   Google Scholar
• Parija PP, Mohan Kumar M. Hepatitis B vaccine birth dose in India: time to reconsider. Hum Vaccin Immunother. 2020;16(1):158–160. doi:10.1080/21645515.2019.1640557.
   PubMed Web of Science ®Google Scholar
• ICF. India national family health survey NFHS-5 2019-21. Mumbai (India): IIPS and ICF; 2022. Available from: https://www.dhsprogram.com/pubs/pdf/FR375/FR375.pdf
   Google Scholar
• ICF. Bangladesh Demographic and Health Survey 2017-18. Dhaka (Bangladesh): NIPORT/ICF; 2020. Available from: https://www.dhsprogram.com/pubs/pdf/FR344/FR344.pdf
   Google Scholar
• National Institute of Population Studies (NIPS) [Pakistan] and ICF. Pakistan demographic and health survey 2017–18. Islamabad (Pakistan); Rockville (MD): NIPS and ICF; 2019.
   Google Scholar
• Pande C, Sarin S, K; Patra S, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies : a randomized controlled trial. J Viral Hepat. 2013;20(11):801–810. doi:10.1111/jvh.12102.
   PubMed Web of Science ®Google Scholar
• Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 2013;31(21):2506–2516. doi:10.1016/j.vaccine.2012.12.012.
   PubMed Web of Science ®Google Scholar
• Afzal MF, Sultan MA, Saleemi AI. Immune response and anamnestic immune response in children after a 3 - dose primary hepatitis B vaccination. J Ayub Med Coll Abbottabad. 2016;28(4):715–717.
   PubMedGoogle Scholar
• Afzal M, Naveed K, Hussain S, et al. Seroprotection after hepatitis B. Vaccin Expanded Prog Immun. 2011;4(4):4–9.
   Google Scholar
• Evdokimov K, Sayasinh K, Nouanthong P, et al. Low and disparate seroprotection after pentavalent childhood vaccination in the Lao people’s democratic republic: a cross-sectional study. Clin Microbiol Infect. 2017;23(3):197–202. doi:10.1016/j.cmi.2016.10.007.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wu Q, Xu B, et al. Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine. 2008;26(48):6064–6067. doi:10.1016/j.vaccine.2008.09.014.
   PubMed Web of Science ®Google Scholar
• Li J, Hu J, Liang X, et al. Predictors of poor response after primary immunization of hepatitis B vaccines for infants and antibody seroprotection of booster in a metropolis of China. Asia Pac J Public Health. 2015;27(2):NP1457–66. doi:10.1177/1010539513496136.
   PubMed Web of Science ®Google Scholar
• Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5(SEP):446. doi:10.3389/fimmu.2014.00446.
   PubMedGoogle Scholar
• Ko SC, Schillie SF, Walker T, et al. Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women. Vaccine. 2014;32(18):2127–2133. doi:10.1016/j.vaccine.2014.01.099.
   PubMed Web of Science ®Google Scholar
• Eze P, Lawani LO, Acharya Y. Short message service (SMS) reminders for childhood immunisation in low-income and middle-income countries: a systematic review and meta-analysis. BMJ Glob Health. 2021;6(7):e005035. doi:10.1136/bmjgh-2021-005035.
   PubMed Web of Science ®Google Scholar
• Kazi AM, Ali M, Zubair K, et al. Effect of mobile phone text message reminders on routine immunization uptake in Pakistan: randomized controlled trial. JMIR Public Health Surveill. 2018;4(1):e20. Available from: http://publichealth.jmir.org/2018/1/e20/ doi:10.2196/publichealth.7026.
   PubMedGoogle Scholar
• Allison RD, Patel MK, Tohme RA. Hepatitis B vaccine birth dose coverage correlates worldwide with rates of institutional deliveries and skilled attendance at birth. Vaccine. 2017;35(33):4094–4098. doi:10.1016/j.vaccine.2017.06.051.
   PubMed Web of Science ®Google Scholar